tbuckley/cabot-search huggingface dataset:
L'infection à VIH en Europe : une importante disparité d'Ouest en Est
Authors: C Semaille, J Alix, A M Downs, F F Hamers
Journal: Eurosurveillance (2003)

En 2001, l'Europe occidentale connait une situation endemique pour le sida (22,8 cas par million d'habitants) et l'infection a VIH (54,9 cas par million), les groupes les plus touches restant les utilisateurs de drogues injectables et les homo/bisexuels masculins. Cependant, les nouveaux diagnostics de VIH augmentent chez les personnes infectees par voie heterosexuelle. L'Europe centrale semble relativement epargnee, l'incidence du sida etant inferieure a 6 cas par million d'habitants quelle que soit l'annee et le taux de nouveaux diagnostics d'infection a VIH variant de 7 a 10 cas par million. En revanche, l'Europe de l'Est affiche une augmentation epidemique du nombre d'infections a VIH (233 cas en 1994, environ 100 000 cas declares en 2001, soit 349 cas par million d'habitants), presente dans tous les pays.
The C gamma 1-encoded disulphide-linked and the C gamma 2-encoded nondisulphide-linked forms of the gamma/delta heterodimer use different gamma and delta variable regions [see comments]
Authors: M Fagioli, E Ciccone, C Bottino, B Falini, F Grignani, A Moretta, L Moretta, PG Pelicci
Journal: Blood (1990)
Case 34-1970
Authors: Richard C. Cabot, Benjamin Castleman, Betty U. McNeely, Martin J. Wohl, John B. Blennerhassett
Journal: New England Journal of Medicine (1970)

Presentation of CaseA 74-year-old man was admitted to the hospital because of dyspnea.He had been well until three years previously, when his physician found that he had hypertension and instituted alpha methyldopa (Aldomet) therapy. Three months before entry he had an episode of substernal pain that radiated to the scapula; the pain subsided in one day. A week later he was admitted to another hospital because of fatigue, weakness and dyspnea. X-ray films of the chest showed an infiltrate in the right upper lobe and a right pleural effusion. A needle biopsy of the lung was interpreted as . . .
Triweekly docetaxel versus biweekly docetaxel as a treatment for advanced castration resistant prostate cancer: Quality of life analysis.
Authors: Pirkko-Liisa Irmeli Kellokumpu-Lehtinen, Ulrika Harmenberg, Petteri Hervonen, Timo K. Joensuu, Raymond S. McDermott, Claes Ginman, Marjaana Luukkaa, Paul Nyandoto, Akseli Hemminki, Sten Nilsson, John McCaffrey, Raija Asola, Taina Turpeenniemi Hujanen, Fredrik Laestadius, Tiina Tasmuth, Katinka Sandberg, Maccon M. Keane, Ilari Lehtinen, Tiina Luukkaala, Heikki Joensuu
Journal: Journal of Clinical Oncology (2014)

23 Background: Bi-weekly docetaxel (T) with prednisone improved progression free survival and overall survival when compared with the standard tri-weekly T as first-line treatment for advanced castration resistant prostate cancer (CRPC) (Lancet Oncol. 2013;14:117-124). We report here the quality of life (QoL) results of this prospective randomized trial. Methods: Three hundred and forty-six patients were randomly allocated centrally to receive intravenous therapy T of either 75 mg/m² d1 q3 wks (the triweekly arm) or 50 mg/m² d1 and d 14, q4 wks (the biweekly arm) (identifier NCT00255606). Prednisone (10 mg/d) was administered orally in both groups. The baseline patients characteristics were well balanced between the groups with respect to the performance status, mean age (69, range 45 to 87 vs. 68, range 46 to 85), and median serum prostate-specific antigen (PSA) content (109 µg/L, range 11 to 1,230 vs. 116 µg/L, range 12 to 1,870). Quality of life (QoL), the frequency and severity of symptoms including pain were assessed using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) version 4.0 questionnaire. Results: The baseline (QoL) of both treatment groups was compared to QoL after six months of the treatment within each treatment group and between groups. Changes in fatigue, symptoms of pain and nausea, and the overall performance status did not differ between the groups. There were statistically significant differences in overall quality of life values (p=0.010) and discomforting pain values (p=0.028) favoring the bi-weekly treatment arm. Conclusions: Bi-weekly T is better tolerated than the tri-weekly standard T. Following the results from the clinical outcome and the QoL outcome in the PROSTY trial we would recommend the use of bi-weekly docetaxel as first line treatment of CRPC Clinical trial information: NCT00255606.
Lung Volume Reduction Coils for Severe Emphysema—Reply
Authors: Gaëtan Deslée, Charles Hugo Marquette
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Right Unilateral Ultrabrief Pulse ECT in Geriatric Depression: Phase 1 of the PRIDE Study
Authors: Charles H Kellner, Mustafa M Husain, Rebecca G Knapp, W Vaughn McCall, Georgios Petrides, Matthew V Rudorfer, Robert C Young, Shirlene Sampson, Shawn M McClintock, Martina Mueller, Joan Prudic, Robert M Greenberg, Richard D Weiner, Samuel H Bailine, Peter B Rosenquist, Ahmad Raza, Styliani Kaliora, Vassilios Latoussakis, Kristen G Tobias, Mimi C Briggs, Lauren S Liebman, Emma T Geduldig, Abeba A Teklehaimanot, Sarah H Lisanby
Journal: American Journal of Psychiatry (2016)

The Prolonging Remission in Depressed Elderly (PRIDE) study evaluated the efficacy of right unilateral ultrabrief pulse electroconvulsive therapy (ECT) combined with venlafaxine for the treatment of geriatric depression.PRIDE was a two-phase multisite study. Phase 1 was an acute course of right unilateral ultrabrief pulse ECT, combined with open-label venlafaxine at seven academic medical centers. In phase 2 (reported separately), patients who had remitted were randomly assigned to receive pharmacotherapy (venlafaxine plus lithium) or pharmacotherapy plus continuation ECT. In phase 1, depressed patients received high-dose ECT (at six times the seizure threshold) three times per week. Venlafaxine was started during the first week of treatment and continued throughout the study. The primary outcome measure was remission, assessed with the 24-item Hamilton Depression Rating Scale (HAM-D), which was administered three times per week. Secondary outcome measures were post-ECT reorientation and safety. Paired t tests were used to estimate and evaluate the significance of change from baseline in HAM-D scores.Of 240 patients who entered phase 1 of the study, 172 completed it. Overall, 61.7% (148/240) of all patients met remission criteria, 10.0% (24/240) did not remit, and 28.3% (68/240) dropped out; 70% (169/240) met response criteria. Among those who remitted, the mean decrease in HAM-D score was 24.7 points (95% CI=23.4, 25.9), with a mean final score of 6.2 (SD=2.5) and an average change from baseline of 79%. The mean number of ECT treatments to remission was 7.3 (SD=3.1).Right unilateral ultrabrief pulse ECT, combined with venlafaxine, is a rapidly acting and highly effective treatment option for depressed geriatric patients, with excellent safety and tolerability. These data add to the evidence base supporting the efficacy of ECT to treat severe depression in elderly patients.
Autologous Hematopoietic Cell Transplantation (HCT) Is Superior To Allogeneic Transplantation For Acute Promyelocytic Leukemia In Second Complete Remission (CR2)
Authors: Morel Rubinger, Andrew Grigg, Frcpa, Jeffrey Szer, George Selby, Jacob M Rowe, Jennifer Le Rademacher, Hailin Wang, Daniel J. Weisdorf, Martin S Tallman
Journal: Blood (2013)
P265 The clinical utility of biomarkers associated with inflammation and endothelial dysfunction in CTEPH: Abstract P265 Table 1
Authors: C Hadinnapola, M Southwood, J Hernandez-Sanchez, K Sheares, S Preston, D Jenkins, N Morrell, M Toshner, J Pepke-Zaba
Journal: Thorax (2015)

<h3>Introduction</h3> Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare form of pulmonary hypertension. Inflammation, defective angiogenesis and endothelial dysfunction have been implicated in its pathogenesis. We assessed the prognostic utility of biomarkers, related to these processes, in pulmonary endarterectomy (PEA) assessment. <h3>Methods</h3> 80 patients with CTEPH had serum samples taken immediately prior to PEA and a subset (n = 54) also at follow-up after PEA. 20 healthy volunteers and 20 patients with idiopathic pulmonary arterial hypertension (IPAH) served as controls. Samples were processed on a custom-designed Luminex multiplex array. Biomarker levels were correlated to haemodynamics and functional assessments. Material removed during PEA and explanted lungs of CTEPH and IPAH patients were additionally analysed using immunostaining. <h3>Results</h3> Compared to healthy controls Pre PEA samples showed increases in interleukin (IL)-8, -10, tumour necrosis factor α (TNFα), high sensitivity C-reactive protein (hsCRP) and angiopoietin 2 (Ang2). Vascular endothelial growth factor (VEGFc) was higher in healthy controls. Following PEA (6.00 ± 1.83 months), improvements in haemodynamics and six-minute walk distance were observed compared to baseline (Table 1). Additionally, there were decreases in Ang2 and Endoglin. Preoperative Ang2 levels were independently associated with baseline pulmonary vascular resistance (PVR) with multiple linear regression (p &lt; 0.0001). A similar association was found in IPAH subjects (p &lt; 0.05). Ang2 expression was demonstrated in the endothelium of distal pulmonary arteries in both IPAH and CTEPH notably in areas of small vessel vasculopathy and in neovessels found in the PEA specimens. The clinical utility in predicting small vessel vasculopathy and residual CTEPH post-PEA surgery was assessed using a cross validation approach. Baseline Ang2 was a necessary component of the best multiple linear model for predicting PVR at follow up (along with baseline PVR, WHO class, age and the use of PAH targeted therapy) r<sup>2</sup> = 0.39, q<sup>2</sup> = 0.35. <h3>Conclusion</h3> We found only modest increases in any marker of inflammation in CTEPH, they were not normalised by PEA or correlated to disease severity. By comparison Ang2 correlated with haemodynamics and has utility in predicting postoperative outcomes.
Strategies to Support Surrogate Decision Makers of Patients With Chronic Critical Illness
Authors: Douglas B. White
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A clinical, controlled study of l-alpha-acetylmethadol in the treatment of narcotic addiction
Authors: M Marcovici, C P O'Brien, A T McLellan, J Kacian
Journal: American Journal of Psychiatry (1981)

The authors compared l-alpha-acetylmethadol (LAAM) with methadone for clinical effectiveness in the treatment of narcotic addiction. LAAM was as effective as methadone on all outcome measures, including length of stay in treatment. Two clinicopharmacologic properties of LAAM caused some patients to ask for a switch to methadone. The authors describe these phenomena and discuss their impact on the clinical effectiveness of LAAM.
Allograft Inflammation and Fibrosis among Maintenance Pediatric Liver Transplant Recipients –Genetic Predisposition and Antibodies, Connecting the Missing Links
Authors: S. Varma, D. Latinne, M. Komuta, J. Ambroise, F. Smets, R. Reding, X. Stephenne, E. Sokal
Journal: Journal of Hepatology (2016)
Clinical implication of internal mammary lymph node biopsy during immediate breast reconstruction using autologous tissue free flaps in breast cancer surgery.
Authors: Han-Byoel Lee, Ki Yong Hong, Jongho Lee, Sangjun Yim, Tae-Yong Kim, Wonshik Han, Ung Sik Jin, Yumi Kim, Jaihong Han
Journal: Journal of Clinical Oncology (2016)

1064 Background: The benefit of internal mammary lymph node (IMLN) biopsy in breast cancer surgery is still debated. This study is aimed to explore clinicopathologic factors associated with IMLN metastasis, and discuss the clinical value of opportunistic biopsy during immediate breast reconstruction using autologous tissue free flap. Methods: We retrospectively reviewed the records of 277 patients who underwent total mastectomy and immediate reconstruction using transverse rectus abdominis musculocutaneous free flap from May 2012 to April 2015. Suspicious IMLN encountered during dissection of 3rd intercostal space for recipient vessels were biopsied. Clinicopathologic characteristics were evaluated in respect to whether the biopsied IMLN had metastasis. Results: During immediate reconstruction, suspicious lymph nodes were identified and biopsied in 53 patients (19.1%, 53/277). Eleven of those patients had a final diagnosis of in situ carcinoma with no IMLN metastasis. Of the 42 patients with invasive carcinoma (15.2%, 42/277), IMLN was positive in 12 patients (28.6%, 12/42). Five patients with positive IMLN had no axillary lymph node metastasis and two of them were upstaged due to the IMLN metastasis. Larger invasive tumor size (p = 0.001) and the presence of lymphatic tumor emboli (p = 0.025) were significantly associated with IMLN metastasis on univariate analysis. Invasive tumor size ≥ 2cm was the only factor associated with IMLN metastasis on multivariate analysis (OR 7.875, 95% CI 1.330-46.628, p = 0.023). Ten of 23 patients with preoperative diagnosis of in situ carcinoma had a final diagnosis of invasive carcinoma and two had IMLN metastasis. Conclusions: Opportunistic biopsy of suspicious IMLN during immediate breast reconstruction using a free flap should be considered in patients with tumor size ≥ 2cm. Selective IMLN biopsy may provide a more accurate staging of the disease, which in turn could lead to appropriate additional treatment that would not have been given without the biopsy.
Access to sterile injecting equipment is important
Authors: C. L Morrison, A. McGee
Journal: BMJ (1996)

Table 1-Prevalence of antibody to H pyloni and C pneumoniae in patients with acute myocardial infarction and controls.Figures are numbers (percentages) Patients with acute myocardial infarction (n = 37) Controls (n = 60) C pneumonlae C pneumonlae C pneumonlse C pneumonlae positive negative positive negative H pylon positive 28 (76) 4 (11) 12 (20) 20 (33) H pylori negative 3 (8) 2 (5) 18 (30) 10 (17)bacteria, mediated by IgE, could be responsible for the enhanced production of interleukin 6.The intense proinflammatory and procoagulant properties of this cytokine could account for most, if not for all, acute coronary syndromes.
Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals
Authors: Fabio Conti, Federica Buonfiglioli, Alessandra Scuteri, Cristina Crespi, Luigi Bolondi, Paolo Caraceni, Francesco Giuseppe Foschi, Marco Lenzi, Giuseppe Mazzella, Gabriella Verucchi, Pietro Andreone, Stefano Brillanti
Journal: Journal of Hepatology (2016)
Inverse Relationship Between the Transcription Repressor Yin Yang 1 (YY1) and the TRAIL Death Receptor DR5 in AIDS-Related Non-Hodgkin's Lymphoma Tissues: Potential Prognostic Biomarkers and Targets for Therapeutic Intervention.
Authors: Sara Huerta-Yepez, Mario I. Vega, Clara Rivera-Pazos, Otoniel Martinez-Maza, James R. Berenson, Benjamin Bonavida
Journal: Blood (2009)
Assessment of the antitumor activity of leech (huridinaria manillensis) saliva extract in prostate cancer.
Authors: Mohamed Hessein, Amr Ammar, Mei Chin, Abdulrahman Abdualkader, Mohamed Alaama, Ahmed Merzouk, Abul Bashar Helaluddin, Abbas Ghawi, Omer Kucuk, Emma Guns
Journal: Journal of Clinical Oncology (2015)

e16120 Background: Ancient traditional physicians from many countries used leeching to treat a wide range of diseases for thousands of years. Leech saliva contains a large number of peptides and proteins, which have anti-thrombotic, antimicrobial, antitumor and anti-metastatic activities. Currently, leech therapy has an established role as an important tool in microsurgery, reconstructive surgery and salvage of grafted tissues. Methods: LSE IC50 was determined in-vitro in five prostate cancer cell lines using MTS cell viability assay. In-vivoefficacy of LSE was determined in LNCaP and 22RV-1 in nude mice xenograft models. Castrated tumor bearing mice were divided into four groups of 6-8 each. Mice were subcutaneously injected with either LSE (5 mg/kg) once a week, LSE (5 mg/kg) twice a week, docetaxel (10 mg/kg) or vehicle twice a week for four weeks. PSA, tumor volume, and weight were measured periodically. Results: In-vitro, LSE induced cell death in a panel of five prostate cancer cell lines. In vivo studies showed that LSE once and twice weekly regimens both caused significant decrease in PSA and tumor volume compared to control with no significant difference from docetaxel treated group. Interestingly, once weekly treatment was associated with significant weight gain (due to good dietary intake) at several time points. Immunohistochemical staining (IHC) showed significant decrease in P21and Ki-67 expression in the LSE treated mice compared to the control group in the LNCaP model. Active caspase-3 was increased at once and twice weekly doses in both models confirming the pro-apoptotic properties of LSE.. Transcriptome analysis of tumor samples showed that LSE had significant immunomodulatory, anti-inflammatory, along with significant effects on cell-cell adhesion, induction of glutathione transferase, inhibition of certain growth factors, and modulating several transcription factors. Conclusions: LSE has significant in vitro and in vivo anti-tumor activity with no apparent side effects. This can be attributed, at least partly, to its ability to inhibit cellular proliferation, induce apoptosis and arrest cell cycle through its modulation of immunity, cell-cell adhesion, and inflammation.
Downregulation of BRCA1 Protein in BCR-ABL1–positive Cells Depends on Tiar-Mediated Repression of BRCA1 mRNA Translation
Authors: Paulina Podszywalow-Bartnicka, Magdalena Wolczyk, Monika Kusio-Kobialka, Kamila Wolanin, Krzysztof Skowronek, Margaret Nieborowska-Skorska, Yashodhara Dasgupta, Tomasz Skorski, Katarzyna Piwocka
Journal: Blood (2014)
Therapy-related myelodysplastic syndrome (t-MDS) following treatment of acute myeloid leukemia (AML)
Authors: C. Arana-Yi, A. W. Block, S. N. Sait, L. A. Ford, M. Barcos, M. R. Baer
Journal: Journal of Clinical Oncology (2007)

17509 Background: t-MDS is well described following treatment of lymphomas, solid tumors and acute promyelocytic leukemia. In contrast, it has been reported only rarely following treatment of AML, possibly because of the smaller percentage of long-term survivors or the difficulty of distinguishing t-MDS from AML relapse. Methods: Roswell Park Cancer Institute (RPCI) patients with a diagnosis of MDS by French-American-British or World Health Organization criteria following a diagnosis of AML were retrospectively reviewed. Results: Five adult patients treated for de novo AML between 1996 and 2005 developed MDS, representing less than 1% of 548 RPCI AML patients during those years. MDS presented as cytopenias and marrow dysplasia, occurred 11 to 101 (median 27) months after diagnosis of de novo AML, and was associated with chromosome 7 abnormalities, including monosomy 7 or del(7q), in all five. All had been treated with cytarabine and topoisomerase II inhibitors and three had received alkylating agents as part of autologous transplant regimens. All had received granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor in conjunction with chemotherapy and/or autologous transplantation. Fluorescence in situ hybridization with the CEP 7 probe or the dual-color LSI D7S486 (7q31)/CEP 7 probe set did not demonstrate chromosome 7 abnormalities in marrow prior to MDS diagnosis nor in peripheral blood stem cells of patients who had undergone autologous transplantation prior to diagnosis of MDS. MDS has progressed slowly in all patients; it evolved to AML in two following 18 and 24 months. Conclusions: These cases further document t-MDS following AML therapy. Presence of chromosome 7 abnormalities in cases without, as well as with, prior alkylating agent therapy suggests possible association with the anti-metabolite cytarabine. No significant financial relationships to disclose.
Cooperation of germ line JAK2 mutations E846D and R1063H in hereditary erythrocytosis with megakaryocytic atypia
Authors: Katarina Kapralova, Monika Horvathova, Christian Pecquet, Jana Fialova Kucerova, Dagmar Pospisilova, Emilie Leroy, Barbora Kralova, Jelena D. Milosevic Feenstra, Fiorella Schischlik, Robert Kralovics, Stefan N. Constantinescu, Vladimir Divoky
Journal: Blood (2016)
Bichat guidelines for the clinical management of botulism and bioterrorism-related botulism
Authors: P Bossi, A Tegnell, A Baka, A Werner, F van Loock, J Hendriks, H Maidhof, G Gouvras
Journal: Eurosurveillance (2004)

Botulism is a rare but serious paralytic illness caused by botulinum toxin, which is produced by the Clostridium botulinum. This toxin is the most poisonous substance known. It 100,000 times more toxic than sarin gas. Eating or breathing this toxin causes illness in humans. Four distinct clinical forms are described: foodborne, wound, infant and intestinal botulism. The fifth form, inhalational botulism, is caused by aerosolised botulinum toxin that could be used as a biological weapon. A deliberate release may also involve contamination of food or water supplies with toxin or C. botulinum bacteria. By inhalation, the dose that would kill 50% of exposed persons (LD50) is 0.003 microgrammes/kg of body weight. Patients with respiratory failure must be admitted to an intensive care unit and require long-term mechanical ventilation. Trivalent equine antitoxins (A,B,E) must be given to patients as soon as possible after clinical diagnosis. Heptavalent human antitoxins (A-G) are available in certain countries.